Aesica Launches New Brand Identity
News Oct 13, 2015
Following its recent acquisition by Consort Medical, Aesica Pharmaceuticals has announced the launch of its new brand identity. This reflects the new alignment and consolidation of the full Consort Medical group.
The combination of Aesica and Bespak enables Consort Medical to provide customers with a single source for drug and device development, formulation, manufacturing and packaging. The group’s unrivalled global offering comprises advanced delivery technologies, formulation development and manufacturing solutions for drugs.
Aesica provides API and finished dose formulation development and manufacturing services. Bespak is a global market leader in the development and manufacture of drug delivery devices.
The new logo and branding will be adopted across all Consort Medical businesses, creating a consistent identity for all group companies. The official launch to the market is planned for 13th October, to coincide with CPhI 2015.
The core vision focuses on delivery of early stage development to full scale manufacturing services that help customers to streamline complex supply chains and, in doing so, accelerates the route of drugs to market, reducing cost and complexity for the group’s partners.
The new logo has been inspired by the ‘joining together’ of the companies – with the three-cornered vertex designed to represent a dynamic company that is at the leading edge of innovation.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018